CLINICAL TRIAL READINESS IN NON-AMBULATORY BOYS AND MEN WITH DUCHENNE MUSCULAR DYSTROPHY: MDA-DMD NETWORK FOLLOW-UP

被引:31
作者
Connolly, Anne M. [1 ,2 ]
Florence, Julaine M. [1 ]
Zaidman, Craig M. [1 ,2 ]
Golumbek, Paul T. [1 ,2 ]
Mendell, Jerry R. [4 ,5 ]
Flanigan, Kevin M. [4 ,5 ]
Karachunski, Peter I. [7 ]
Day, John W. [8 ]
Mcdonald, Craig M. [6 ]
Darras, Basil T. [9 ]
Kang, Peter B. [10 ]
Siener, Catherine A. [1 ]
Gadeken, Rebecca K. [1 ]
Anand, Pallavi [1 ]
Schierbecker, Jeanine R. [1 ]
Malkus, Elizabeth C. [1 ]
Lowes, Linda P. [4 ,5 ]
Alfano, Lindsay N. [4 ,5 ]
Johnson, Linda [6 ]
Nicorici, Alina [6 ]
Kelecic, Jason M. [7 ]
Quigley, Janet [9 ]
Pasternak, Amy E. [9 ]
Miller, J. Philip [3 ]
机构
[1] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA
[4] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA
[5] Nationwide Childrens Hosp, Ctr Gene Therapy, Columbus, OH USA
[6] Univ Calif Davis, Med Ctr, Dept Phys Med & Rehabil, Sacramento, CA 95817 USA
[7] Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA
[8] Stanford Univ, Dept Neurol, Stanford, CA 94305 USA
[9] Harvard Univ, Boston Childrens Hosp, Dept Neurol, Boston, MA 02115 USA
[10] Univ Florida, Coll Med, Div Pediat Neurol, Gainesville, FL USA
基金
美国国家卫生研究院;
关键词
Brooke Scale; clinical trial; Duchenne muscular dystrophy; Egen Klassifikation Scale; force vital capacity; non-ambulatory; outcomes; PULMONARY-FUNCTION; GLUCOCORTICOID TREATMENT; NATURAL-HISTORY; PROGRESSION; VALIDATION; PREDNISONE; CHILDREN; SURVIVAL; THERAPY; DISEASE;
D O I
10.1002/mus.25089
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Outcomes sensitive to change over time in non-ambulatory boys/men with Duchenne muscular dystrophy (DMD) are not well-established. Methods: Subjects (n = 91; 16.8 +/- 4.5 years old) were assessed at baseline and 6-month intervals for 2 years. We analyzed all subjects using an intent-to-treat model and a subset of stronger subjects with Brooke Scale score <= 4, using repeated measures. Results: Eight patients (12-33 years old) died during the study. Sixty-six completed 12-month follow-up, and 51 completed 24-month follow-up. Those taking corticosteroids performed better at baseline, but rates of decline were similar. Forced vital capacity percent predicted (FVC% predicted) declined significantly only after 2 years. However, Brooke and Egen Klassifikation (EK) Scale scores, elbow flexion, and grip strength declined significantly over both 1 and 2 years. Conclusion: Brooke and EK Scale scores, elbow flexion, and grip strength were outcomes most responsive to change. FVC% predicted was responsive to change over 2 years. Corticosteroids benefited non-ambulatory DMD subjects but did not affect decline rates of measures tested here.
引用
收藏
页码:681 / 689
页数:9
相关论文
共 40 条
[1]   Correlations of Egen Klassifikation and Barthel Index scores with pulmonary function parameters in Duchenne muscular dystrophy [J].
Afonso Brunherotti, Marisa ;
Sobreira, Claudia ;
Luiz Rodrigues-Junior, Antnio ;
Renato de Assis, Marcos ;
Terra Filho, Joao ;
Baddini Martinez, Jose Antonio .
HEART & LUNG, 2007, 36 (02) :132-139
[2]  
[Anonymous], AM J OCCUP THER
[3]   Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study [J].
Bello, Luca ;
Gordish-Dressman, Heather ;
Morgenroth, Lauren P. ;
Henricson, Erik K. ;
Tina Duong ;
Hoffman, Eric P. ;
Cnaan, Avital ;
McDonald, Craig M. .
NEUROLOGY, 2015, 85 (12) :1048-1055
[4]   CLINICAL INVESTIGATION IN DUCHENNE DYSTROPHY .2. DETERMINATION OF THE POWER OF THERAPEUTIC TRIALS BASED ON THE NATURAL-HISTORY [J].
BROOKE, MH ;
FENICHEL, GM ;
GRIGGS, RC ;
MENDELL, JR ;
MOXLEY, R ;
MILLER, JP ;
PROVINCE, MA .
MUSCLE & NERVE, 1983, 6 (02) :91-103
[5]   DUCHENNE MUSCULAR-DYSTROPHY - PATTERNS OF CLINICAL PROGRESSION AND EFFECTS OF SUPPORTIVE THERAPY [J].
BROOKE, MH ;
FENICHEL, GM ;
GRIGGS, RC ;
MENDELL, JR ;
MOXLEY, R ;
FLORENCE, J ;
KING, WM ;
PANDYA, S ;
ROBISON, J ;
SCHIERBECKER, J ;
SIGNORE, L ;
MILLER, JP ;
GILDER, BF ;
KAISER, KK ;
MANDEL, S ;
ARFKEN, C .
NEUROLOGY, 1989, 39 (04) :475-481
[6]   Myostatin does not regulate cardiac hypertrophy or fibrosis [J].
Cohn, Ronald D. ;
Liang, Hsin-Yueh ;
Shetty, Reena ;
Abraham, Theodore ;
Wagner, Kathryn R. .
NEUROMUSCULAR DISORDERS, 2007, 17 (04) :290-296
[7]   OUTCOME RELIABILITY IN NON-AMBULATORY BOYS/MEN WITH DUCHENNE MUSCULAR DYSTROPHY [J].
Connolly, Anne M. ;
Malkus, Elizabeth C. ;
Mendell, Jerry R. ;
Flanigan, Kevin M. ;
Miller, J. Philip ;
Schierbecker, Jeanine R. ;
Siener, Catherine A. ;
Golumbek, Paul T. ;
Zaidman, Craig M. ;
McDonald, Craig M. ;
Johnson, Linda ;
Nicorici, Alina ;
Karachunski, Peter I. ;
Day, John W. ;
Kelecic, Jason M. ;
Lowes, Linda P. ;
Alfano, Lindsay N. ;
Darras, Basil T. ;
Kang, Peter B. ;
Quigley, Janet ;
Pasternak, Amy E. ;
Florence, Julaine M. .
MUSCLE & NERVE, 2015, 51 (04) :522-532
[8]   Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation [J].
Eagle, M ;
Baudouin, SV ;
Chandler, C ;
Giddings, DR ;
Bullock, R ;
Bushby, K .
NEUROMUSCULAR DISORDERS, 2002, 12 (10) :926-929
[9]   A COMPARISON OF DAILY AND ALTERNATE-DAY PREDNISONE THERAPY IN THE TREATMENT OF DUCHENNE MUSCULAR-DYSTROPHY [J].
FENICHEL, GM ;
MENDELL, JR ;
MOXLEY, RT ;
GRIGGS, RC ;
BROOKE, MH ;
MILLER, JP ;
PESTRONK, A ;
ROBISON, J ;
KING, W ;
SIGNORE, L ;
PANDYA, S ;
FLORENCE, J ;
SCHIERBECKER, J ;
WILSON, B .
ARCHIVES OF NEUROLOGY, 1991, 48 (06) :575-579
[10]   LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophy [J].
Flanigan, Kevin M. ;
Ceco, Ermelinda ;
Lamar, Kay-Marie ;
Kaminoh, Yuuki ;
Dunn, Diane M. ;
Mendell, Jerry R. ;
King, Wendy M. ;
Pestronk, Alan ;
Florence, Julaine M. ;
Mathews, Katherine D. ;
Finkel, Richard S. ;
Swoboda, Kathryn J. ;
Gappmaier, Eduard ;
Howard, Michael T. ;
Day, John W. ;
McDonald, Craig ;
McNally, Elizabeth M. ;
Weiss, Robert B. .
ANNALS OF NEUROLOGY, 2013, 73 (04) :481-488